钙通道阻滞剂和疼痛治疗。

Current review of pain Pub Date : 2000-01-01 DOI:10.1007/s11916-000-0073-8

B Cox

{"title":"钙通道阻滞剂和疼痛治疗。","authors":"B Cox","doi":"10.1007/s11916-000-0073-8","DOIUrl":null,"url":null,"abstract":"This review focuses on the advances in the development of N-type calcium channel blockers as analgesic agents over the last 2 years. Firstly, it highlights the clinical progress with SNX-111 (Ziconotide; Elan Pharmaceuticals, Smithfield, RI) and then secondly, it outlines the various approaches being taken by researchers to design orally active, selective, small molecule modulators without the perceived disadvantages associated with SNX-111.","PeriodicalId":80271,"journal":{"name":"Current review of pain","volume":"4 6","pages":"488-98"},"PeriodicalIF":0.0000,"publicationDate":"2000-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11916-000-0073-8","citationCount":"34","resultStr":"{\"title\":\"Calcium channel blockers and pain therapy.\",\"authors\":\"B Cox\",\"doi\":\"10.1007/s11916-000-0073-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This review focuses on the advances in the development of N-type calcium channel blockers as analgesic agents over the last 2 years. Firstly, it highlights the clinical progress with SNX-111 (Ziconotide; Elan Pharmaceuticals, Smithfield, RI) and then secondly, it outlines the various approaches being taken by researchers to design orally active, selective, small molecule modulators without the perceived disadvantages associated with SNX-111.\",\"PeriodicalId\":80271,\"journal\":{\"name\":\"Current review of pain\",\"volume\":\"4 6\",\"pages\":\"488-98\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s11916-000-0073-8\",\"citationCount\":\"34\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current review of pain\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s11916-000-0073-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current review of pain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11916-000-0073-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 34

摘要

本文综述了近2年来n型钙通道阻滞剂作为镇痛药的研究进展。首先，重点介绍了SNX-111(齐iconotide;其次，它概述了研究人员正在采用的各种方法，以设计口服活性，选择性，小分子调节剂，而没有与SNX-111相关的已知缺点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Calcium channel blockers and pain therapy.

This review focuses on the advances in the development of N-type calcium channel blockers as analgesic agents over the last 2 years. Firstly, it highlights the clinical progress with SNX-111 (Ziconotide; Elan Pharmaceuticals, Smithfield, RI) and then secondly, it outlines the various approaches being taken by researchers to design orally active, selective, small molecule modulators without the perceived disadvantages associated with SNX-111.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current review of pain

自引率

0.00%

发文量

期刊最新文献

Is the term "pain disorder" a valid diagnosis? Epidemic occupational pseudo-illness: the plague of acronyms. The debate over chronic pain continues Controversies surrounding reflex sympathetic dystrophy: a review article. Reflex sympathetic dystrophy: a sympathetically mediated pain syndrome or not?